MEDIA RELEASE

Release Status	For immediate release	**Ref**	1202DIA
Product Enquiries	**Diatron Group** **International contact:** Brian Conibere International Sales and Marketing Manager t: 44 1234 880697 M: 44 7717 856815 e: brian.conibere@diatron.com **In the USA:** Pat Galvin t: 1 913 344 9955 e: pat.galvin@diatron.com		
Media enquiries	**Alto Marketing Limited** Catherine Clarke t: +44 (0)1489 557672 e: catherinec@alto-marketing.com Twitter: @AltoMarketing w: www.alto-marketing.com		

New Facilities Hail Diatron's Growing Success

Modern production unit in Hungary houses clinical chemistry and hematology analyzers under one roof

[Contact catherinec@alto-marketing.com for high res image]

BUDAPEST, HUNGARY (October 29, 2012): In response to their continued growth in the *in-vitro* diagnostics market, Diatron, a global provider of hematology and clinical chemistry analyzers, has moved to new, larger modern facilities in Budapest, Hungary. The move enables Diatron to consolidate their production and support of their clinical chemistry and hematology analyzers onto one site. After the initial opening on October 10th, the state-of-the-art site will allow the company to respond more quickly to market needs and enhance their R & D efforts.

MEDIA RELEASE

The news follows the recent US Food and Drug Administration (FDA) approval of two of the company's hematology analyzers, the Abacus 3CP, 3-part differential analyzer and Abacus 5, 5-part differential analyzer.

With more than 30,000 hematology analyzers already sold in over 100 international markets, the creation of the new production facilities, together with the US FDA approvals, are important milestones that have strengthened Diatron's global position, opening up many additional opportunities in the US market.

According to Ronald Backes, Vice President of International Business Development at Diatron, "One of the outcomes of the new production facility will be to concentrate our research and design efforts. This will allow us to ensure we are producing analyzers that match our customer's needs and provide an optimum service in terms of reliability, efficiency and cost-effectiveness".

For more information please visit the Diatron Group website: http://www.diatron.com

Editors' Notes

The Diatron Group

Diatron's vision since the company's foundation in 1989, is to become a worldwide leader *in-vitro* diagnostics, providing customers with a broad portfolio of high-quality tailored solutions. In its new production facility in Budapest, Hungary, the extensive R&D/Engineering team develops and manufactures compact hematology analyzers and reagents for the human medical and veterinary markets.

Diatron is a portfolio company of, The Riverside Company, a global private equity firm focused on acquiring growing businesses valued at up to $200 million (€200 million in Europe). Founded in 1988, Riverside's international portfolio now includes 80 companies, and it has more than $3 billion/€2.5 billion in assets under management.
See www.riversidecompany.com for more information